A detailed history of Bank Of America Corp transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 49,210 shares of LRMR stock, worth $303,133. This represents 0.0% of its overall portfolio holdings.

Number of Shares
49,210
Previous 46,581 5.64%
Holding current value
$303,133
Previous $337,000 4.45%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$6.3 - $10.68 $16,562 - $28,077
2,629 Added 5.64%
49,210 $322,000
Q2 2024

Aug 14, 2024

BUY
$6.33 - $9.89 $43,411 - $67,825
6,858 Added 17.26%
46,581 $337,000
Q1 2024

May 15, 2024

BUY
$4.2 - $13.28 $62,349 - $197,141
14,845 Added 59.67%
39,723 $301,000
Q4 2023

Feb 14, 2024

SELL
$2.35 - $4.71 $92,176 - $184,745
-39,224 Reduced 61.19%
24,878 $113,000
Q2 2023

Aug 14, 2023

BUY
$3.13 - $5.27 $129,053 - $217,287
41,231 Added 180.28%
64,102 $200,000
Q1 2023

May 12, 2023

BUY
$4.0 - $6.68 $91,228 - $152,350
22,807 Added 35635.94%
22,871 $103,000
Q4 2022

Feb 10, 2023

BUY
$2.73 - $5.08 $166 - $309
61 Added 2033.33%
64 $0
Q3 2022

Nov 14, 2022

SELL
$1.53 - $3.64 $321 - $764
-210 Reduced 98.59%
3 $0
Q2 2022

Aug 12, 2022

SELL
$1.9 - $3.98 $220,419 - $461,719
-116,010 Reduced 99.82%
213 $0
Q1 2022

May 16, 2022

BUY
$3.65 - $10.84 $159,552 - $473,848
43,713 Added 60.29%
116,223 $471,000
Q4 2021

Feb 08, 2022

SELL
$8.86 - $13.47 $82,398 - $125,271
-9,300 Reduced 11.37%
72,510 $782,000
Q3 2021

Nov 15, 2021

BUY
$9.61 - $15.11 $722,441 - $1.14 Million
75,176 Added 1133.19%
81,810 $944,000
Q2 2021

Sep 13, 2021

BUY
$8.0 - $15.2 $53,072 - $100,836
6,634 New
6,634 $65,000

Others Institutions Holding LRMR

About Larimar Therapeutics, Inc.


  • Ticker LRMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,269,200
  • Market Cap $267M
  • Description
  • Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...
More about LRMR
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.